LSB Stock Overview
A biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
LakeShore Biopharma Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.57 |
| 52 Week High | US$11.20 |
| 52 Week Low | US$1.88 |
| Beta | 0.74 |
| 11 Month Change | 0.78% |
| 3 Month Change | -42.25% |
| 1 Year Change | -58.55% |
| 33 Year Change | -96.22% |
| 5 Year Change | n/a |
| Change since IPO | -96.13% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%
Nov 01
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough
Jun 25Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues
May 08Shareholder Returns
| LSB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.8% | -6.5% | -1.0% |
| 1Y | -58.5% | 14.6% | 30.3% |
Return vs Industry: LSB underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: LSB underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| LSB volatility | |
|---|---|
| LSB Average Weekly Movement | 24.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LSB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LSB's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 758 | Wang Xu | www.ysbiopharm.com |
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines.
LakeShore Biopharma Co., Ltd Fundamentals Summary
| LSB fundamental statistics | |
|---|---|
| Market cap | US$49.99m |
| Earnings (TTM) | -US$59.90m |
| Revenue (TTM) | US$79.24m |
0.6x
P/S Ratio-0.8x
P/E RatioIs LSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSB income statement (TTM) | |
|---|---|
| Revenue | CN¥573.42m |
| Cost of Revenue | CN¥187.36m |
| Gross Profit | CN¥386.06m |
| Other Expenses | CN¥819.52m |
| Earnings | -CN¥433.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.72 |
| Gross Margin | 67.33% |
| Net Profit Margin | -75.59% |
| Debt/Equity Ratio | 71.3% |
How did LSB perform over the long term?
See historical performance and comparison